The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRAL | +458.93% | N/A | N/A | +484% |
| S&P | +14.5% | +93.32% | +14.09% | +24% |
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $35.54M | 11.2% |
| Gross Profit | -$22.37M | -24.9% |
| Gross Margin | -62.93% | -6.9% |
| Market Cap | $1.85B | 287.6% |
| Market Cap / Employee | $1.85M | 0.0% |
| Employees | 1K | 0.0% |
| Net Income | -$113.99M | 92.8% |
| EBITDA | -$92.79M | 48.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $127.43M | -86.7% |
| Accounts Receivable | $16.31M | 21.7% |
| Inventory | 19.7 | -22.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $48.48M | -22.0% |
| Short Term Debt | $13.69M | -1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.83% | 0.0% |
| Return On Invested Capital | -77.62% | -0.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$77.33M | 55.3% |
| Operating Free Cash Flow | -$76.97M | 55.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.16 | 0.23 | 0.35 | 0.75 | 489.34% |
| Price to Sales | 3.88 | 4.82 | 6.70 | 13.71 | 215.17% |
| Price to Tangible Book Value | 0.70 | 1.11 | 1.78 | 4.21 | 74.39% |
| Enterprise Value to EBITDA | 2.59 | 0.92 | -2.33 | -14.01 | -725.18% |
| Return on Equity | -65.9% | -62.2% | -17.7% | - | |
| Total Debt | $72.19M | $68.14M | $64.32M | $62.16M | -18.32% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
